Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              F. Hoffmann-La Roche

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              USP Workshop 2021

              Participation Not Confirmed

              Update your events

              Roche Writes Off Ulcerative Colitis Portion of Etrolizumab Program, Days After Dissecting Phase III Setback

              Contact the Supplier

              Lead Product(s): Etrolizumab,Adalimumab

              Therapeutic Area: Gastroenterology Product Name: RG7413

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 15, 2020

              Details:

              After disappointing Phase III results Roche has decided to discontinue etrolizumab program as an ulcerative colitis treatment. The drug failed meet its primary endpoint compared to Remicade.

              F. Hoffmann-La Roche

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWITZERLAND Switzerland

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              USP Workshop 2021

              Participation Not Confirmed

              Update your events

              Roche Provides Update on Phase III Studies of Etrolizumab In People with Moderately to Severely Active Ulcerative Colitis

              Contact the Supplier

              Lead Product(s): Etrolizumab,Adalimumab

              Therapeutic Area: Gastroenterology Product Name: RG7413

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 10, 2020

              Details:

              Etrolizumab met its primary endpoint of inducing remission versus placebo for people with ulcerative colitis in only two of three studies.

              PharmaCompass__DigitalAd